Evidence map›Paper›PMID 42125973›Full record

ArticleBiotechnology journal2026

Regression Models of Viability and Apoptosis Can be Generated Leveraging Cluster Analysis From Ovizio iLineF PRO Image Data.

Joseph Fantuzzo, Nicholas Zill, John Bowers, Balrina Gupta

Abstract read
In one paragraph

Article in Biotechnology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Joseph FantuzzoBiologics Process Development, MRL, Merck & Co., Inc., Rahway, New Jersey, USA.ORCID https://orcid.org/0000-0002-2580-0392
Nicholas ZillData Rich Experimentation, Enabling Technologies, MRL, Merck & Co., Inc., Rahway, New Jersey, USA.
John BowersData Rich Experimentation, Enabling Technologies, MRL, Merck & Co., Inc., Rahway, New Jersey, USA.
Balrina GuptaBiologics Process Development, MRL, Merck & Co., Inc., Rahway, New Jersey, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chinese hamster ovary (CHO) cells serve as the backbone of modern large-scale manufacturing of monoclonal antibodies. Central to this process are fed-batch cultures, where cells are grown from low to high cell densities and go through a mAb production phase. Despite CHO cells' widespread usage and vital role in the production of biologics, the cellular states during fed-batch coinciding with high specific productivity and apoptosis are poorly understood. Crucial to this understanding is a clear depiction of the various subpopulations of cells that exist in a fed-batch culture over time. In this work, an Ovizio iLine F PRO was used to image the cells in benchtop bioreactors and gather morphological and optical information for several CHO cell lines. A cluster analysis was applied to the Ovizio iLine F PRO raw data, revealing a diverse set of cellular sub-populations within each culture. Raw data from the Ovizio were then transformed into tank-level data and applied to offline measurements for viability and apoptosis in regression analysis. We used the results from the cluster analysis and feature averaging to set up regressions for offline measurements. Our regression analysis illustrates the power of in-line imaging of CHO cells as a rich process analytical tool.

Indexed as

ApoptosisAnimalsAntibodies, MonoclonalBatch Cell Culture TechniquesBioreactorsCell SurvivalCHO CellsCluster AnalysisClustering AlgorithmsCricetinaeCricetulusRegression AnalysisAntibodies, Monoclonalapoptosisbioprocess developmentbioreactorcell culturecell healthmachine learningmodelingovizioregressionUMAP

Identifiers

PMID42125973
PMCPMC13383605

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.